Medical Therapy to Block Aberrant Hormone Receptors for Bilateral Macronodular Adrenal Hyperplasia
STEP 1 — Gather Information
Confirm BMAH diagnosis with bilateral adrenal nodules on CT/MRI and hormonal evidence of autonomous cortisol secretion (elevated UFC, non‑suppressible cortisol). Assess patient preference and surgical feasibility. Perform adrenal vein sampling or hormone challenge tests (meal, GIP, LH/hCG, serotonin) to identify aberrant hormone receptors driving cortisol excess.
STEP 2 — Rule In / Rule Out
Rule in aberrant hormone receptor expression if hormone challenge provokes a cortisol rise >20% or adrenal vein sampling shows receptor‑linked secretion; rule out if no such reactivity is detected.
STEP 3 — Classify or Stratify
Classify the aberrant receptor type (e.g., GIP receptor, LH/hCG receptor, serotonin receptor, adrenal androgen receptor) to guide selection of specific antagonist therapy.
STEP 4 — Decide
Initiate medical therapy targeting the identified aberrant receptor (e.g., ketoconazole or metyrapone for steroidogenesis inhibition, or receptor‑specific antagonists such as cyproheptadine for serotonin, GnRH antagonist for LH/hCG, or investigational GIP antagonist) with the goal of normalizing cortisol levels.
Clinical Guardrails / Mimics / Pitfalls
Do not use receptor‑blocking therapy when surgery is feasible and preferred; avoid in patients with known hypersensitivity to the chosen agent; monitor for adrenal insufficiency and hypocortisolism; do not rely solely on receptor blockade if cortisol remains elevated, as adjunctive steroidogenesis inhibition may be needed; avoid agents that stimulate cortisol secretion (e.g., exogenous ACTH).
Concrete Clinical Example
A 48‑year‑old woman with bilateral adrenal nodules on CT, unsuppressed cortisol, declines surgery due to cardiac risk. Adrenal vein sampling after oral GIP shows a 45% cortisol rise, indicating aberrant GIP receptor. She is started on ketoconazole 400 mg twice daily; after 3 weeks UFC falls to normal range and symptoms improve.
Source: Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline, Nieman et al., 2015, DOI: 10.1210/jc.2015-1818